Editorial
doi: 10.1200/JCO.2010.32.2693.
Epub 2010 Dec 20.
Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy
- PMID: 21172885
- DOI: 10.1200/JCO.2010.32.2693
Item in Clipboard
Editorial
Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy
J Clin Oncol.
.
No abstract available
Comment on
-
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172891 Clinical Trial.
Similar articles
-
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172891 Clinical Trial.
-
[Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia].Rinsho Ketsueki. 2007 Jun;48(6):458-67. Rinsho Ketsueki. 2007. PMID: 17633093 Review. Japanese. No abstract available.
-
Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.Haematologica. 2004 Jun 1;89(6 Suppl):ECR18. Haematologica. 2004. PMID: 15194554 No abstract available.
-
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721
-
[Combination chemotherapy for acute myeloid leukemia].Nihon Rinsho. 2009 Oct;67(10):1921-5. Nihon Rinsho. 2009. PMID: 19860191 Review. Japanese.
Cited by
-
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289. Nat Biotechnol. 2012. PMID: 22781692
-
Enediynes: Exploration of microbial genomics to discover new anticancer drug leads.Bioorg Med Chem Lett. 2015 Jan 1;25(1):9-15. doi: 10.1016/j.bmcl.2014.11.019. Epub 2014 Nov 14. Bioorg Med Chem Lett. 2015. PMID: 25434000 Free PMC article. Review.
-
Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.Cancer Sci. 2012 Sep;103(9):1722-9. doi: 10.1111/j.1349-7006.2012.02343.x. Epub 2012 Jul 11. Cancer Sci. 2012. PMID: 22632031 Free PMC article.
-
Drug-conjugated antibodies for the treatment of cancer.Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Br J Clin Pharmacol. 2013. PMID: 23173552 Free PMC article. Review.
-
Site-specific antibody drug conjugates for cancer therapy.MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022. MAbs. 2014. PMID: 24423619 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
